menu
    • menu
    [{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"5-Methyltetrazole","moa":"A2AR\/BR","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0.26000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.26000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Domain Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Domain Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"5-Methyltetrazole","moa":"A2AR\/BR","graph1":"Oncology","graph2":"Phase I","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"EMD Serono \/ Merck Group"}]

    Find Clinical Drug Pipeline Developments & Deals for 5-Methyltetrazole

    Menu

    5-Methyltetrazole

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Domain Therapeutics

                            France arrow
                            AAPS
                            Not Confirmed

                            Domain Therapeutics

                            France arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 5-Methyltetrazole

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Merck & Co

                            Deal Size : $261.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Domain Therapeutics Receives a Single Digit Multimillion Development Milestone Payment from Merck For M1069 Cl...

                            Details : A2a/A2b antagonist candidate, M1069, a first-in-human study to investigate the safety, tolerability, PK/PD and clinical activity in patients with metastatic or locally advanced unresectable solid tumors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 28, 2022

                            Lead Product(s) : 5-Methyltetrazole

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Merck & Co

                            Deal Size : $261.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EMD Serono

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            EMD Serono

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 5-Methyltetrazole

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First in Human Study of M1069 in Advanced Solid Tumors

                            Details : M1069 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 20, 2022

                            Lead Product(s) : 5-Methyltetrazole

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth